The good news is that so far Geron's pattern has not been to announce the filing of the IND, but rather the approval, so we're unlikely to have those wild swings if FDA "requests more information." The detractors will likely, however, make much ado about the matter if no approval announcement is made by eoy.
Geeze, they're still harping on 163/163L. The lab work, according to and old and trusted poster on that other board, was the lab DNA uses. DNA being their big dog, they put Geron's tests behind DNA. When looking at this, remember there were a gazillion tests required meaning a large time block devoted to the exercise, so the lab couldn't just "squeeze" them in here or there. Dr. O referenced that Geron was not in control of the testing - one of those instances where one needs to VERY CAREFULLY listen to what he says. I think it is to Geron's credit that they used the wait time to develop the "L," rather than looking at it as the bashers have of late as something on the order of researchers fiddling around not focused on getting "a" product to market.
Point being, remember there are variables, not all of which are controlled by the company or their work.
UPOD seems to be a good strategy, until you consider what the screeching would be if Dr. O said the IND was something like 5 years out. LOL
>> And on the embryonic stem cell side, the big one is, of course, to complete our IND enabling studies, file our IND for spinal cord injury and begin in '07 the world's first human clinical trial using embryonic stem cells. We want to move the cardiomyocytes into large animals and demonstrate normalized glucose with our islets in animal models of diabetes.<<
Market Data 
Markets 
AI
